Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study - Scorecard - MDSpire
Advertisement
Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study
Clinical Scorecard: Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study
At a Glance
Category
Detail
Condition
Moderate-to-Severe Atopic Dermatitis
Key Mechanisms
Tralokinumab neutralizes interleukin-13 (IL-13)
Target Population
Adolescents aged 12-17 years with moderate-to-severe atopic dermatitis
Care Setting
Clinical trial setting
Key Highlights
Tralokinumab treatment showed improvements in AD signs and symptoms compared to placebo.
Most laboratory parameters remained within reference ranges throughout the study.
Transient elevation in eosinophil levels observed; IgE levels decreased in tralokinumab groups.
No clinically significant changes in laboratory parameters were noted.
Routine laboratory monitoring is not required for tralokinumab treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis of moderate-to-severe AD based on clinical assessment.
Management
Tralokinumab is recommended as a systemic treatment for moderate-to-severe AD.
Monitoring & Follow-up
Routine laboratory monitoring is not necessary during tralokinumab treatment.
Risks
Limited safety concerns compared to traditional systemic immunosuppressants.
Patient & Prescribing Data
Adolescents aged 12-17 years with moderate-to-severe AD.
Tralokinumab (150 or 300 mg) administered subcutaneously every 2 or 4 weeks.
Clinical Best Practices
Consider tralokinumab for adolescents with moderate-to-severe AD.
Monitor clinical response rather than laboratory parameters.
by Amy S. Paller, Michael J. Cork, H. Chih-ho Hong, Weily Soong, Shannon K. R. Schneider, Hannah Lo, Frank Vinther, Patrick Thøgersen, Andreas Wollenberg
